The DOI matches its Crossref record; 19 of the 20 references it cites were found in a registry or an index.
Metformin Associated With Lower Cancer Mortality in Type 2 Diabetes
Open accessAbstract
OBJECTIVE: Several studies have suggested an association between specific diabetes treatment and cancer mortality. We studied the association between metformin use and cancer mortality in a prospectively followed cohort. RESEARCH DESIGN AND METHODS: In 1998 and 1999, 1,353 patients with type 2 diabetes were enrolled in the Zwolle Outpatient Diabetes project Integrating Available Care (ZODIAC) study in the Netherlands. Vital status was assessed in January 2009. Cancer mortality rate was evaluated using standardized mortality ratios (SMRs), and the association between metformin use and cancer mortality was evaluated with a Cox proportional hazards model, taking possible confounders into account. RESULTS: Median follow-up time was 9.6 years, average age at baseline was 68 years, and average A1C was 7.5%. Of the patients, 570 died, of which 122 died of malignancies. The SMR for cancer mortality was 1.47 (95% CI 1.22–1.76). In patients taking metformin compared with patients not taking metformin at baseline, the adjusted hazard ratio (HR) for cancer mortality was 0.43 (95% CI 0.23–0.80), and the HR with every increase of 1 g of metformin was 0.58 (95% CI 0.36–0.93). CONCLUSIONS: In general, patients with type 2 diabetes are at increased risk for cancer mortality. In our group, metformin use was associated with lower cancer mortality compared with nonuse of metformin. Although the design cannot provide a conclusion about causality, our results suggest a protective effect of metformin on cancer mortality.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Several epidemiologic studies have shown that metformin use is associated with reduced cancer incidence and mortality (Landman et al., 2010; Lee et al., 2011; Libby et al., 2009; Monami et al., 2011; Tseng, 2012).”
From Metformin as a tool to target aging (2016) · cites this paper as Landman et al., 2010
In the citing paper
“The reduced risk of cancer and cancer mortality observed in these studies has been consistently in the range of 25% to 30% [135-139,145-147].”
From Metformin: An Old But Still the Best Treatment for Type 2 Diabetes (2013) · cites this paper as [138]
In the citing paper
“A prospective study (median follow-up time of 9.6 years) found that metformin use at baseline was associated with lower cancer-related mortality and that this association appeared to be dose dependent [138].”
From Metformin: An Old But Still the Best Treatment for Type 2 Diabetes (2013) · cites this paper as [138]
In the citing paper
“Metformin use is associated with lower cancer-related mortality.”
From Metformin: An Old But Still the Best Treatment for Type 2 Diabetes (2013) · cites this paper as [138]
In the citing paper
“Patients with type 2 diabetes who are prescribed metformin had a lower risk of cancer compared to patients who did not take it.”
From Metformin: An Old But Still the Best Treatment for Type 2 Diabetes (2013) · cites this paper as [138]
In the citing paper
“When compared to those on other treatments, metformin users had a lower risk of cancer. A dose-relationship has been reported [138,144,145].”
From Metformin: An Old But Still the Best Treatment for Type 2 Diabetes (2013) · cites this paper as [138]
In the citing paper
“Results of a growing number of observational human studies suggest that treatment with metformin (relative to other glucose-lowering therapies) is associated with reduced risk of cancer (89–93) or cancer mortality (94).”
From Diabetes and Cancer (2010) · cites this paper as [94]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Metformin and reduced risk of cancer in diabetic patients
Evans, J. M. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R., & Morris, A. D. (2005) · BMJ · doi:10.1136/bmj.38415.708634.f7 · Cited by 2,388
The influence of glucose-lowering therapies on cancer risk in type 2 diabetes
Currie, C. J., Poole, C. D., & Gale, E. A. M. (2009) · Diabetologia · doi:10.1007/s00125-009-1440-6 · Cited by 1,124
New Users of Metformin Are at Low Risk of Incident Cancer
Libby, G., Donnelly, L. A., Donnan, P. T., Alessi, D. R., Morris, A. D., & Evans, J. M. M. (2009) · Diabetes Care · doi:10.2337/dc08-2175 · Cited by 996
Bowker, S. L., Majumdar, S. R., Veugelers, P., & Johnson, J. A. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1558 · Cited by 933
Jiralerspong, S., Palla, S. L., Giordano, S. H., Meric-Bernstam, F., Liedtke, C., Barnett, C. M., Hsu, L., Hung, M.-C., Hortobagyi, G. N., & Gonzalez-Angulo, A. M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.19.6410 · Cited by 880 · cited 1×
“For example, type 2 diabetic patients receiving neoadjuvant chemotherapy for breast cancer as well as metformin were more likely to have a complete remission than patients not receiving metformin (14).”
Sahra, I. B., Laurent, K., Loubat, A., Giorgetti-Peraldi, S., Colosetti, P., Auberger, P., Tanti, J. F., Le Marchand-Brustel, Y., & Bost, F. (2008) · Oncogene · doi:10.1038/sj.onc.1211024 · Cited by 861
Diabetes Mellitus as a Predictor of Cancer Mortality in a Large Cohort of US Adults
Coughlin, S. S., Calle, E. E., Teras, L. R., Petrelli, J. M., & Thun, M. J. (2004) · American Journal of Epidemiology · doi:10.1093/aje/kwh161 · Cited by 795
Hemkens, L. G., Grouven, U., Bender, R., Günster, C., Gutschmidt, S., Selke, G. W., & Sawicki, P. T. (2009) · Diabetologia · doi:10.1007/s00125-009-1418-4 · Cited by 607
Antidiabetic Therapies Affect Risk of Pancreatic Cancer
Li, D., Yeung, S. J., Hassan, M. M., Konopleva, M., & Abbruzzese, J. L. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.04.013 · Cited by 584
Prospective Study of Adult Onset Diabetes Mellitus (Type 2) and Risk of Colorectal Cancer in Women
Hu, F. B., Manson, J. E., Liu, S., Hunter, D. J., Colditz, G. A., Michels, K. B., Speizer, F. E., & Giovannucci, E. L. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.6.542 · Cited by 420
Flagged first, then by citations
1 of the 20 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 301–400 of 503
Alnasrallah, B., Pilmore, H., & Manley, P. (2017) · BMJ Open · doi:10.1136/bmjopen-2017-016813 · Cited by 19
Patient‐ and Cell Type‐Specific Heterogeneity of Metformin Response
Asiedu, M. K., Barron, M., Aubry, M. C., & Wigle, D. A. (2017) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12898 · Cited by 19
Tumor reversion: a dream or a reality
Tripathi, A., Kashyap, A., Tripathi, G., Yadav, J., Bibban, R., Aggarwal, N., Thakur, K., Chhokar, A., Jadli, M., Sah, A. K., et al. (2021) · Biomarker Research · doi:10.1186/s40364-021-00280-1 · Cited by 19
Diabetes and risk of tumors: oncologic considerations
Rosta, A. (2011) · Orvosi Hetilap · doi:10.1556/oh.2011.29158 · Cited by 19
Targeting the Electron Transport System for Enhanced Longevity
Radovic, M., Gartzke, L. P., Wink, S. E., van der Kleij, J. A., Politiek, F. A., & Krenning, G. (2025) · Biomolecules · doi:10.3390/biom15050614 · Cited by 17
Chung, W.-S., Le, P., Kuo, C. J., Chen, T., Kuo, C., Chiou, M., Chou, W., Yeh, T., & Hsu, J. (2020) · Cancers · doi:10.3390/cancers12082013 · Cited by 18
Barrios‐Bernal, P., Zatarain-Barrón, Z. L., Hernández‐Pedro, N., Orozco‐Morales, M., Olivera-Ramírez, A., Ávila‐Moreno, F., Colín-González, A. L., Cardona, A. F., Rosell, R., & Arrieta, O. G. (2022) · Pharmaceuticals · doi:10.3390/ph15070786 · Cited by 18
Therapeutic effects of metformin in breast cancer: involvement of the immune system?
Schott, S., Bierhaus, A., Schütz, F., Beckhove, P., Schneeweiß, A., Sohn, C., & Domschke, C. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1062-y · Cited by 19
Glargine safety, diabetes and cancer
Rendell, M., Aktürk, H. K., & Tella, S. H. (2013) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2013.770469 · Cited by 18
The Relationship Between Metformin and Serum Prostate‐Specific Antigen Levels
Jayalath, V. H., Ireland, C., Fleshner, N. E., Hamilton, R. J., & Jenkins, D. J. A. (2016) · The Prostate · doi:10.1002/pros.23228 · Cited by 18
Alkhatib, Y., Rahman, Z. A., & Kuriakose, P. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1239822 · Cited by 18
Sun, L., Yao, H.-J., Li, J.-C., Zhao, B., Wang, Y., & Zhang, Y. (2023) · International Journal of Nanomedicine · doi:10.2147/ijn.s382519 · Cited by 17
Diabetes, insulin and cancer risk
Yang, X. (2012) · World Journal of Diabetes · doi:10.4239/wjd.v3.i4.60 · Cited by 17
Sluik, D., Boeing, H., Montonen, J., Kaaks, R., Lukanova, A., Sandbæk, A., Overvad, K., Arriola, L., Ardanáz, E., Saieva, C., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038877 · Cited by 17
Feng, J., & Qin, X. S. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108755 · Cited by 17
Lee, D.-J., Kim, B., Lee, J. H., Park, S. J., Hong, S. P., Cheon, J. H., Kim, T. I., & Kim, W. H. (2012) · Korean Journal of Gastroenterology · doi:10.4166/kjg.2012.60.6.355 · Cited by 17
Roelofsen, Y., Hendriks, S. H., Sieverink, F., van Vugt, M., van Hateren, K. J., Snoek, F. J., de Wit, M., Gans, R. O. B., Groenier, K. H., van Gemert‐Pijnen, J. E. W. C., et al. (2014) · BMC Endocrine Disorders · doi:10.1186/1472-6823-14-22 · Cited by 17
Self-citationPark, D. (2019) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b19-00474 · Cited by 17
Using metformin in the presence of renal disease
Chowdhury, T. A., Wright, R., & Yaqoob, M. (2015) · BMJ · doi:10.1136/bmj.h1758 · Cited by 17
Shete, M. B., Deshpande, A. S., & Shende, P. K. (2022) · Chemistry and Physics of Lipids · doi:10.1016/j.chemphyslip.2022.105256 · Cited by 16
Prognostic value of metformin in cancers: An updated meta-analysis based on 80 cohort studies
Yang, J., Yang, H., Cao, L., Yin, Y., Shen, Y., & Zhu, W. (2022) · Medicine · doi:10.1097/md.0000000000031799 · Cited by 17
Yang, H., Wu, C.-Y., Powell, J. D., & Lu, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21114030 · Cited by 17
Association of Metformin and Abdominal Aortic Aneurysm Repair Outcomes
Turowicz, A., Kobecki, J., Laskowska, A., Wojciechowski, J., Świątkowski, F., & Chabowski, M. (2021) · Annals of Vascular Surgery · doi:10.1016/j.avsg.2021.02.048 · Cited by 16
Metformin and Cancer in Type 2 Diabetes
Park, H. K. (2013) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2013.37.2.113 · Cited by 16
The Anti-Breast Cancer Effect and Mechanism of Glimepiride-Metformin Adduct
Long, L., Hu, X., Li, X., Zhou, D., Shi, Y., Wang, L., Zeng, H., Yu, X., & Zhou, W. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s240252 · Cited by 15
Cui, Y., Zhou, J., & Rong, F. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.09.135 · Cited by 15
Impact of diabetes on prognosis of gastric cancer patients performed with gastrectomy
Chen, X., Chen, Y., Li, T., Jun, L., Lin, T., Huang, H., Huang, H., Liu, H., Liu, H., Li, G., et al. (2020) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2020.05.08 · Cited by 15
Activation of AMPK sensitizes medulloblastoma to Vismodegib and overcomes Vismodegib‐resistance
Gampala, S., Zhang, G., Chang, C. J., & Yang, J. (2021) · FASEB BioAdvances · doi:10.1096/fba.2020-00032 · Cited by 15
Research progress on the therapeutic effect and mechanism of metformin for lung cancer (Review)
Han, P., Zhou, J., Xiang, J., Liu, Q., & Sun, K. (2022) · Oncology Reports · doi:10.3892/or.2022.8440 · Cited by 16
Curry, A., Khatri, I. A., Kos, O., Zhu, F., & Gorczynski, R. M. (2017) · PLoS ONE · doi:10.1371/journal.pone.0171586 · Cited by 15
Schwartz, S. S., Grant, S. F. A., & Herman, M. E. (2019) · Postgraduate Medicine · doi:10.1080/00325481.2019.1657358 · Cited by 16
Metformin and Breast Cancer Risk
Gandini, S., Guerrieri‐Gonzaga, A., Puntoni, M., & DeCensi, A. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.3596 · Cited by 15
Interlinking of diabetes mellitus and cancer: An overview
Ahmad, I., Suhail, M., Ahmad, A., Alhosin, M., & Tabrez, S. S. M. (2023) · Cell Biochemistry and Function · doi:10.1002/cbf.3802 · Cited by 14
Luo, C.-S., Lin, Y., Zhou, W., & Shi, J. (2019) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000001610 · Cited by 14
Zhu, R. C., Rattanakorn, K., Pham, S., Mallam, D., McIntyre, T. P., Salifu, M. O., Youssef, I., McFarlane, S. I., & Vignesh, S. (2017) · Colorectal Cancer · doi:10.2217/crc-2017-0001 · Cited by 14
Metformin Associated With Lower Cancer Mortality in Type 2 Diabetes: ZODIAC-16
Ovalle, F. (2010) · Yearbook of Medicine · doi:10.1016/s0084-3873(10)79790-x · Cited by 14
Discovering Biological Mechanisms of Exceptional Human Health Span and Life SpanPreprint
Milman, S., & Barzilai, N. (2023) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041204 · Cited by 14
Kim, S. H., Kang, J. G., Kim, C. S., Ihm, S., Choi, M. G., Yoo, H. J., & Lee, S. J. (2017) · Endocrine · doi:10.1007/s12020-017-1503-2 · Cited by 13
Doherty, D. T., Coe, P. O., Rimmer, L. J., Lapsia, S., Krige, A., & Subar, D. A. (2019) · Surgical Oncology · doi:10.1016/j.suronc.2019.07.007 · Cited by 14
Metabolism and cancer-select topics
Lonardo, F., & Ballouk, C. (2022) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2022.05 · Cited by 13
Metformin displays in vitro and in vivo antitumor effect against osteosarcoma
Ko, Y., Choi, A., Lee, M., & Lee, J. A. (2016) · Korean Journal of Pediatrics · doi:10.3345/kjp.2016.59.9.374 · Cited by 13
Metabolic Syndrome and Breast Cancer Risk: Is There a Role for Metformin?
Ibarra-Drendall, C., Dietze, E. C., & Seewaldt, V. L. (2011) · Current Breast Cancer Reports · doi:10.1007/s12609-011-0050-8 · Cited by 13
Zhang, B., Cao, Y. Y., Qu, Z., Sun, Y., & Tian, X. (2024) · Endocrine · doi:10.1007/s12020-024-04012-x · Cited by 12
Pan, Y., Lin, C., Lu, C., Li, L., Wang, Y., Chen, H., & He, Y. (2018) · The Clinical Respiratory Journal · doi:10.1111/crj.12970 · Cited by 12
Jiang, X., Zhang, Y., Wang, W., Sheng, D., Zhou, X., & Li, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.608238 · Cited by 12
Yamanashi, T., Anderson, Z. M., Modukuri, M., Chang, G., Tran, T., Marra, P. S., Wahba, N. E., Crutchley, K. J., Sullivan, E. J., Jellison, S. S., et al. (2022) · Aging · doi:10.18632/aging.204393 · Cited by 12
Review of approved pioglitazone combinations for type 2 diabetes
Forst, T. M., Hanefeld, M., & Pfützner, A. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.567266 · Cited by 12
Wang, Y., Bai, H., Zhang, R., Yan, H., Ning, K., & Zhao, X. (2017) · Oncotarget · doi:10.18632/oncotarget.21398 · Cited by 12
Natural-Agent Mechanisms and Early-Phase Clinical Development
Wang, J. L., Gold, K. A., & Lippman, S. M. (2012) · Topics in current chemistry · doi:10.1007/128_2012_341 · Cited by 12
ERADicate Tumor Progression with Metformin
Dreher, L.-S., & Hoppe, T. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.08.001 · Cited by 12
Cancer risk according to fasting blood glucose trajectories: a population-based cohort study
Khong, T. M. T., Bui, T. T., Kang, H., Lee, J., Park, E., & Oh, J. (2024) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2023-003696 · Cited by 11
Wang, G., Li, X., Xiong, R., Wu, H., Xu, M., & Xie, M. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13398 · Cited by 11
Reduced Mortality Associated With the Use of Metformin Among Patients With Autoimmune Diseases
Lin, C., Wu, C., Hsu, C.-Y., Chen, T., Lin, M., Lin, Y., & Su, Y. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.641635 · Cited by 11
Han, J. H., Kim, J. H., Lee, J.-W., Han, S. H., & Kim, H. (2022) · Scientific Reports · doi:10.1038/s41598-022-07768-2 · Cited by 11
Kawakita, E., Yang, F., Shi, S., Takagaki, Y., Koya, D., & Kanasaki, K. (2023) · Cancers · doi:10.3390/cancers15184529 · Cited by 11
Spoerl, S., Gerken, M., Schimnitz, S., Taxis, J., Fischer, R., Lindner, S. R., Ettl, T., Ludwig, N., Spoerl, S., Reichert, T. E., et al. (2022) · Current Oncology · doi:10.3390/curroncol29120758 · Cited by 11
Metformin and Pancreatic Cancer Metabolism
Cantoria, M. J., Patel, H., Boros, L. G., & Meuillet, E. J. (2014) · InTech eBooks · doi:10.5772/57432 · Cited by 13
New Paradigms in the Clinical Management of Li–Fraumeni SyndromePreprint
Giovino, C., Subasri, V., Telfer, F., & Malkin, D. M. (2024) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041584 · Cited by 12
Preventive effects of 13 different drugs on colorectal cancer: a network meta-analysis
Fu, Q., Liao, H., Li, Z., Chen, X., Zhang, X., & Di, J. (2023) · Archives of Medical Science · doi:10.5114/aoms/167480 · Cited by 10
Tsai, M., Lee, P., Lin, C., Peng, C., & Kao, C. (2014) · International Journal of Cancer · doi:10.1002/ijc.29292 · Cited by 10
Mitocans: Mitochondrially Targeted Anti-cancer Drugs
Boukalová, Š., Rohlenová, K., Rohlena, J., & Neužil, J. (2018) · Springer eBooks · doi:10.1007/978-3-319-73344-9_27 · Cited by 12
Metformin Indications, Dosage, Adverse Reactions, and Contraindications
Stoica, R. A., Ștefan, D. S., Rizzo, M., Suceveanu, A., Suceveanu, A. P., Serafinceanu, C., & Stoian, A. P. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.88675 · Cited by 11
Nowicka, Z., Matyjek, A., Płoszka, K., Łaszczych, M., & Fendler, W. M. (2023) · Pancreatology · doi:10.1016/j.pan.2023.01.007 · Cited by 10
Metformin for lung cancer prevention and improved survival: a novel approach
Roos, J. F., Qudsi, M., Samara, A., Rahim, M. M., Al-Bayedh, S. A., & Ahmed, H. (2018) · European Journal of Cancer Prevention · doi:10.1097/cej.0000000000000442 · Cited by 11
Hereditary syndromes with signs of premature aging
Golounina, O. O., Fadeev, V. V., & Belaya, Z. E. (2020) · Osteoporosis and Bone Diseases · doi:10.14341/osteo12331 · Cited by 9
Multidimensional mechanisms of metformin in cancer treatment
Makkar, S. S., Pandav, K. B., Hathaway, D., Paul, T., & Youssef, P. (2021) · Tumori Journal · doi:10.1177/03008916211023548 · Cited by 9
Matsubayashi, S., Ito, S., Araya, J., & Kuwano, K. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1079626 · Cited by 13
Insights into targeting LKB1 in tumorigenesis
Trelford, C. B., & Shepherd, T. G. (2024) · Genes & Diseases · doi:10.1016/j.gendis.2024.101402 · Cited by 10
Interest and challenges of pharmacoepidemiology for the study of drugs used in diabetes
Salvo, F., & Faillie, J. (2018) · Therapies · doi:10.1016/j.therap.2018.09.074 · Cited by 9
Stem cell damage after chemotherapy- can we do better?
Tang, J., Zhu, N., Rao, S., & Carlson, K.-S. (2019) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2019.02.001 · Cited by 9
Qiu, J., Yard, B. A., Krämer, B. K., van Goor, H., van Dijk, P. R., & Kannt, A. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.899057 · Cited by 9
Popov, V., & Lim, J. K. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1875 · Cited by 9
Role and application of hysterosalpingography and Fallopian tube recanalization.
Mallarini, G., & Saba, L. (2010) · PubMed · Cited by 9
Villegas‐Vázquez, E. Y., Marín-Carrasco, F. P., Reyes‐Hernández, O. D., Báez-González, A. S., Bustamante-Montes, L. P., Padilla‐Benavides, T., Granados, L. I. Q., & Figueroa‐González, G. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2024.1514120 · Cited by 8
de Haan-Du, J., Groenier, K. H., Wauben-Spaetgens, B., Jalving, M., Kleefstra, N., Landman, G. W. D., & de Bock, G. H. (2022) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-22-0766 · Cited by 8
Self-citationCushing Syndrome Is Associated With a Higher Risk of Cancer—A Nationwide Cohort Study
Wu, W.-C., Wu, J.-L., Huang, T., Li, C., & Li, H. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae405 · Cited by 8
Hamedi, B., Khalili, A., Roozmeh, S., Namazi, G., & Saraf, Z. (2018) · International Journal of Cancer Management · doi:10.5812/ijcm.11621 · Cited by 8
Therapeutic potential of the antidiabetic drug metformin in small bowel adenocarcinoma
Chiyo, T., Kato, K., Iwama, H., Fujihara, S., Fujita, K., Tadokoro, T., Oura, K., Samukawa, E., Yamana, Y., Kobayashi, N., et al. (2017) · International Journal of Oncology · doi:10.3892/ijo.2017.3971 · Cited by 8
Metformina: Uma Revisão da Literatura
Neto, E. M. R., Valadas, L. A. R., Ferreira, M. A. D., Lobo, P. L. D., Júnior, F. J. G., Camarão, G. C., & de Moraes, M. E. A. (2015) · Saúde e Pesquisa · doi:10.17765/1983-1870.2015v8n2p355-362 · Cited by 8
Zeng, S., Tang, Q., Jiang, K., & Tang, X. (2022) · Process Biochemistry · doi:10.1016/j.procbio.2022.11.016 · Cited by 7
A Cohort Study of Exposure to Antihyperglycemic Therapy and Survival in Patients with Lung Cancer
Danila, E., Linkevičiūtė-Ulinskienė, D., Zablockis, R., Gruslys, V., Cicėnas, S., & Smailytė, G. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17051747 · Cited by 7
Current Status of Chemoprevention in Barrett’s Esophagus
Moayyedi, P., & El‐Serag, H. B. (2020) · Gastrointestinal Endoscopy Clinics of North America · doi:10.1016/j.giec.2020.08.008 · Cited by 7
Impaired glucose metabolism treatment and carcinogenesis
Matyszewski, A., Czarnecka, A. M., Kawecki, M., KORZEŃ, P., SAFIR, I. J., Kukwa, W., & Szczylik, C. A. (2015) · Oncology Letters · doi:10.3892/ol.2015.3324 · Cited by 7
Metformin as a Novel Component of Metronomic Chemotherapeutic Use: A Hypothesis
Duque, J. E., Vélez, J., Samudio, I. J., & Lai, E. (2012) · Journal of Experimental & Clinical Medicine · doi:10.1016/j.jecm.2012.04.002 · Cited by 7
Use of metformin is associated with lower incidence of cancer in patients with type 2 diabetes
Muszyńska-Ogłaza, A., Zarzycka-Lindner, G., Olejniczak, H., Polaszewska-Muszyńska, M., & Junik, R. (2015) · Endokrynologia Polska · doi:10.5603/ep.a2017.0054 · Cited by 7
Metformin - more than 'gold standard' in the treatment of type 2 diabetes mellitus.
Marić, A. (2010) · Diabetologia Croatica · Cited by 7
Quels bénéfices antitumoraux attendre de la metformine ?
Beck, E., & Scheen, A. J. (2013) · Annales d Endocrinologie · doi:10.1016/j.ando.2013.02.009 · Cited by 6
de Haan-Du, J., Kleefstra, N., Schrijnders, D., Groenier, K. H., de Bock, G. H., & Landman, G. W. D. (2020) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-19-1517 · Cited by 7
Self-citationFröhlich, E., & Wahl, R. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01491.x · Cited by 6
de Haan-Du, J., Landman, G. W. D., Groenier, K. H., Vissers, P. A. J., Louwman, M. W. J., Kleefstra, N., & de Bock, G. H. (2021) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-21-0620 · Cited by 6
Self-citationMecanismos antitumorales de la metformina: señalización, metabolismo, inmunidad y más allá.
Duque, J. E., López, C., Cruz, N., & Samudio, I. J. (2010) · Universitas Scientiarum · doi:10.11144/javeriana.sc15-2.amom · Cited by 6
The role of metformin in the modern strategy of treatment and prevention of type 2 diabetes mellitus
Smirnova, O. M. (2010) · Diabetes Mellitus · doi:10.14341/2072-0351-5494 · Cited by 6
Strategies for the treatment of breast cancer: from classical drugs to mathematical models
Costa, A., & Vale, N. (2021) · Mathematical Biosciences & Engineering · doi:10.3934/mbe.2021316 · Cited by 7
Unger, J. (2011) · Diabetes Therapy · doi:10.1007/s13300-010-0014-4 · Cited by 5
Brzački, V., Nagorni, A. V., Kallistratos, M. S., Manolis, A. J., & Lović, D. B. (2019) · Current Pharmacology Reports · doi:10.1007/s40495-019-00183-8 · Cited by 5
Ali, M. A., Khalil, M. M., Al‐Mokaddem, A. K., Aljuaydi, S. H., Ahmed, M. M., & Khalil, H. M. A. (2022) · Applied Radiation and Isotopes · doi:10.1016/j.apradiso.2022.110305 · Cited by 5
Viollet, B., & Foretz, M. (2011) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(11)70183-3 · Cited by 5
Costa, D., Ceccato, F., Lauretta, R., Mercuri, V., D’Amico, T., Vito, C. D., Scaroni, C. M., Appetecchia, M., & Gargiulo, P. (2021) · International Journal of Clinical Oncology · doi:10.1007/s10147-021-01895-y · Cited by 5
Wu, J., Zhou, Y., & Gui-zhou, W. (2021) · Gastroenterology Research and Practice · doi:10.1155/2021/9468227 · Cited by 5
Metadata
- Authors
- Landman, G. W. D., Kleefstra, N., van Hateren, K. J. J., Groenier, K. H., Gans, R. O. B., & Bilo, H. J. G.
- Affiliations
- Isala (NL)
- Diabetes Centre, Isala Clinics, Zwolle, the Netherlands;
- University Medical Center Groningen (NL)
- Corresponding author
- Landman, Gijs W.D.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2009-11-16
- Volume
- 33
- Issue
- 2
- Pages
- 322-326
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC2809274
- OpenAlex
- W2058725063
- Cited by
- 502
- References
- 20
- Citations by year
- 2026: 5 · 2025: 7 · 2024: 11 · 2023: 17 · 2022: 28 · 2021: 24 · 2020: 31 · 2019: 23 · 2018: 28 · 2017: 30 · 2016: 25 · 2015: 39 · 2014: 41 · 2013: 54 · 2012: 48
- FWCI
- 18.64
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion, other-oa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Keywords
- metformin, cancer mortality, type 2 diabetes, diabetes drugs, cancer risk, standardized mortality ratio
- MeSH terms
- Aged, Blood Pressure, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Female, Glycated Hemoglobin, Humans, Hypertension, Hypoglycemic Agents, Insulin, Male, Metformin, Middle Aged, Neoplasms, Netherlands, Prospective Studies, Risk Factors, Smoking, Cohort Studies, Body Mass Index
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
